Actively Recruiting

Phase 4
Age: 18Years - 80Years
All Genders
ID05718128

Clinical Study of Endocardial Myocardial Biopsy

Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2023-03-28

100

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the safety of endocardial myocardial biopsy in patients with heart conditions such as myocarditis, cardiomyopathy, heart failure, and cardiac tumors of unknown cause. This clinical study aims to observe the operation's safety and perform pathological examinations, including special tests like viral examination, mass spectrometry, and molecular biology, to confirm diagnoses. The study is led by the Second Affiliated Hospital, School of Medicine, Zhejiang University and is a phase 4 interventional trial. The study involves patients undergoing the endocardial myocardial biopsy procedure, which is being assessed for safety and diagnostic value. If necessary, additional specialized tests are performed on biopsy samples to better understand the underlying cardiac condition. Participants are those who receive this biopsy procedure at the hospital and meet the study's eligibility criteria. During the study, researchers will follow participants over time to monitor safety and outcomes, including the incidence of major adverse cardiovascular events (MACE-4) over a 10-year period. Participants will be observed and assessed through pathological examinations and follow-up visits. The study began in June 2021 and is planned to continue until June 2031, providing long-term safety data.

CONDITIONS

Brief Title

Clinical Study of Endocardial Myocardial Biopsy

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients of any gender aged 18 to 80 years old receiving endocardial myocardial biopsy at the Second Affiliated Hospital of Zhejiang University School of Medicine
  • Diagnosed with myocarditis, cardiomyopathy, heart failure, or cardiac tumor of unknown clinical cause
  • Able to understand the test and cooperate with study investigators
Not Eligible

You will not qualify if you...

  • Unable or unwilling to understand or sign informed consent forms
  • Unable or unwilling to attend follow-up visits

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Diagnostic Evaluation

Duration - 1 day

Participants undergo an endocardiomyocardial biopsy to assess their heart condition.

1 visit (in-person)

Long-term Monitoring

Duration - 10 years

Participants are monitored for major adverse cardiac events (MACE) over a period of 10 years after the biopsy.

Follow-up visits over 10 years

Trial Site Locations

Total: 1 location

1

2nd Affiliated Hospital, School of Medicine, Zhejiang University, China

Hangzhou, Zhejiang, China

Actively Recruiting

Loading map...

Research Team

X

XiaoHong PAN

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Similar Trials

Extensive Post-discharge Counselling and Phone-based Follow-...

Heart Failure

Actively Recruiting

1 location

Three-Dimensional Assessment of Right Ventricular Function i...

Heart Failure

Actively Recruiting

1 location

Myocardial Fibrosis in Heart Failure: A Pilot Study Using 68...

Myocardial Fibrosis

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here